Bio-Rad Laboratories has experienced numerous critical events in the recent past, affecting their stock performance. Following the
launch of four ddPCR platforms, Bio-Rad's stocks saw a spike. However, the firm's performance took a shortfall with
Q4 revenue and guidance missing expectations, leading to a
4% drop in stocks. This prompted analysis questioning whether Bio-Rad is
undervalued considering its low debt and price drop. In counterbalance, the firm
offered to acquire Stilla, implying a possible rise in the BIO stock. On the downside, Bio-Rad shareholders have experienced further losses since the stock declined
14% in a week, taking three-year losses to 53%, the company is
navigating financial challenges. Conversely, expert
analysts foresee strong growth rates and unmatched profit potential validating the BIO stock. The company
completed the acquisition of Stilla Technologies and has an investment in
Sartorius both potentially driving long-term value, despite the
52-week low amid market shifts.
Institutional investors currently own 60% of the company.
Bio-Rad Laboratories Stocks News Analytics from Mon, 13 Feb 2017 08:00:00 GMT to Sat, 19 Jul 2025 12:09:15 GMT -
Rating -5
- Innovation 4
- Information 8
- Rumor -3
